COHANCE IN EQUITY
loading…—
Day range—
52-week range—
Market cap—
P/E · TTM—
As of—
| CUSTOMER | BASIS | EST ₹CR | RANGE | % REV | BUCKET | PERIOD | METHOD | CONF |
|---|---|---|---|---|---|---|---|---|
| Business | REV SHARE | 2,042 | 2,042–2,042 | 90.0% | — | FY26 | DISC | 90% |
| “Details of business activities (accounting for 90% of the turnover) Sr. No. Description of Main Activity Description of Business Activity % of Turnover of the …” AR · +2 DOC | ||||||||
| Business | REV SHARE | 1,089 | 1,089–1,089 | 48.0% | R&D | FY26 | DISC | 90% |
| “two additional customer molecules are expected to enter commercial supply in 12-18 months Pipeline 10 Customer molecules in Phase III 13 DMF / CEP filings Comp…” AR DOC | ||||||||
| FY27 | UNSTATED | — | — | — | — | FY27 | EST | 75% |
| “Two of these molecules have since entered commercial supply, with deliveries scheduled across Q2 and Q3 FY27.” AR · +2 DOC | ||||||||
| PPLPHARMAPiramal Pharma Ltd. | UNSTATED | — | — | — | — | FY25 | EST | 75% |
| “Prior to joining Cohance, he served as CEO of Piramal Pharma Solutions (2014-19), where he played a key role in expanding the Company’s global footprint and dr…” AR DOC | ||||||||
| GRANULESGranules India Ltd. | UNSTATED | — | — | — | — | FY25 | EST | 75% |
| “Before his current roles, he served as Executive Director at Granules India Ltd., where he played a pivotal role in shaping the Company’s growth strategy, mana…” AR DOC | ||||||||
| INFYInfosys Ltd. | UNSTATED | — | — | — | SG&A | FY25 | EST | 75% |
| “Over his distinguished tenure, he held several key roles, including Delivery Head for Europe, Head of Solution Consulting, Head of Infrastructure Management Se…” AR DOC | ||||||||
| Australia | UNSTATED | — | — | — | SG&A | FY25 | EST | 75% |
| “Over his distinguished tenure, he held several key roles, including Delivery Head for Europe, Head of Solution Consulting, Head of Infrastructure Management Se…” AR DOC | ||||||||
| United States | UNSTATED | — | — | — | R&D | FY26 | EST | 70% |
| “Headquartered in Hyderabad, Telangana, India, the Company operates manufacturing, research and development (R&D) and commercial facilities across India and the…” AR DOC | ||||||||
| China. | UNSTATED | — | — | — | — | FY26 | EST | 70% |
| “Mitigation Measures l Leveraged China Plus One and EU Plus One opportunities through the integrated India-US operating model, providing customers with credible…” AR DOC | ||||||||
| United States | UNSTATED | — | — | — | COGS | FY26 | EST | 70% |
| “The Company serves global pharmaceutical innovators, biotechnology companies, generic pharmaceutical customers and speciality-chemical innovators through opera…” AR DOC | ||||||||
| Securities and Exchange Board of India | UNSTATED | — | — | — | — | FY26 | EST | 70% |
| “The Securities and Exchange Board of India (Registrars to an Issue and Share Transfer Agents) Regulations, 1993 regarding the Act and dealing with client;” AR · +1 DOC | ||||||||
| Others | UNSTATED | — | — | — | — | FY26 | EST | 70% |
| “pdf Customers Yes 0 0 0 0 Value Chain Partners Yes 0 0 0 0 Others - - 0 0 0 0 Annual Report 2025-26167Statutory Reports 30.” AR DOC | ||||||||
| BANKINDIABank of India | UNSTATED | — | — | — | — | FY26 | EST | 70% |
| “The compounding application was made by Erstwhile Cohance and upon the merger of the Erstwhile Cohance with the Company, the Company is the successor and has t…” AR DOC | ||||||||
| Securities and Exchange Board of India | UNSTATED | — | — | — | R&D | FY26 | EST | 70% |
| “We being a global Contract Development and Manufacturing Operations (CDMO) company are committed to follow and practice our core values to advance solutions fo…” AR · +1 DOC | ||||||||
| Authority. | UNSTATED | — | — | — | — | FY26 | EST | 70% |
| “Description Cases Shares % Equity 1 Foreign Promoter Bodies Corporates 2 21,99,30,170 57.49 2 Bodies Corporates 655 2,75,40,273 7.20 3 Clearing Members 4 1,021…” AR DOC | ||||||||
| Buyer | UNSTATED | — | — | — | — | FY26 | EST | 70% |
| “Description Cases Shares % Equity 1 Foreign Promoter Bodies Corporates 2 21,99,30,170 57.49 2 Bodies Corporates 655 2,75,40,273 7.20 3 Clearing Members 4 1,021…” AR DOC | ||||||||
| Financial Year | UNSTATED | — | — | — | — | FY25 | EST | 70% |
| “b) In our opinion and according to the information and explanations given to us, the Company has transferred the remaining unspent amounts towards Corporate So…” AR · +1 DOC | ||||||||
| Mumbai | UNSTATED | — | — | — | — | FY26 | EST | 70% |
| “Hon’ble National Company Law Tribunal, Mumbai Bench, vide its order dated October 24, 2024 has sanctioned the Scheme of Amalgamation for the merger of Casper w…” AR · +1 DOC | ||||||||
| United States | UNSTATED | — | — | — | — | FY25 | EST | 70% |
| “These investments also deepen our presence in the United States and enhance proximity to key biopharma customers.” AR DOC | ||||||||
| Business | UNSTATED | — | — | — | COGS | FY25 | EST | 70% |
| “DELIVER We collaborate with our customers to enhance their molecules and products, enabling them to deliver innovative solutions to their patients and consumer…” AR DOC | ||||||||
| FY27 | UNSTATED | — | — | — | COGS | FY27 | EST | 60% |
| “Of the two programs that recently entered commercialization, we have recently received orders for one involving four intermediates, with the other that is also…” CONCALL DOC | ||||||||
| SUPPLIER | BASIS | EST ₹CR | RANGE | % COST | BUCKET | PERIOD | METHOD | CONF |
|---|---|---|---|---|---|---|---|---|
| UNITDSPRUnited Spirits Ltd. | UNSTATED | — | — | — | — | FY26 | EST | 75% |
| “He currently serves as an Independent Director at Eureka Forbes Limited and Cohance Lifesciences Limited, and acts as a Trustee for the UK-based Isha Foundatio…” AR DOC | ||||||||
| Business | UNSTATED | — | — | — | R&D | FY25 | EST | 75% |
| “BUSINESS VERTICAL-1PHARMA CDMO 4848%% Contribution to Combined Platform Revenue in FY25 Presence l We are supplying to 16 commercial molecules of our innovator…” AR DOC | ||||||||
| United States | UNSTATED | — | — | — | R&D | FY26 | EST | 70% |
| “SIGNIFICANT INDIRECT ECONOMIC IMPACTS The Company’s investments in manufacturing infrastructure, R&D capabilities and differentiated technology platforms have …” AR DOC | ||||||||
| SOURCE | READ | % | LAST READ |
|---|---|---|---|
| ANNUAL | 2/2 | 100% | 15-OCT-26 |
| CONCALL | 4/4 | 100% | 15-OCT-26 |
| RATINGS | 0/2 | 0% | — |
| SCREENER | 1/1 | 100% | 10-NOV-26 |
| SIGNAL | VALUE | AS OF | INPUTS |
|---|---|---|---|
| CUST MOM 1M | +14.7% | 14-NOV-26 | from 15-OCT-26 · Bank of India +18.2% w 0 · Piramal Pharma Ltd. +25.8% w 0 · Granules India Ltd. +0.2% w 0 |
| DISTRESS SCORE | 0.332 | 13-OCT-26 | roe 0.04 · operatingMargin 0.19 · debtToEquity 0.1 · interestCoverage 6.59 · assetTurnover 0.4 · leverage 1.46 |
| SUPP MOM 1M | +2.6% | 14-NOV-26 | from 15-OCT-26 · United Spirits Ltd. +2.6% |